Redeye comments on Magle’s profit warning ahead of its Q4 and full-year 2025 results, which we see as a direct outcome of the recently annou...
Redeye comments on Magle’s strategic pivot toward profitability, operational discipline, and sustainable value creation.
Delays weigh down the quarter’s results.
Redeye provides a comment following Magle’s announcement that it is exploring the issuance of senior secured bonds of up to SEK300m, within ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech company Saving Chlora AB.
Redeye provides a research update following the Q4 report recently published by Magle.
Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial with leading European university hospita...
Redeye leaves a comment following Magle’s recent announcement of a directed share issue of approximately SEK26.
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK36.
Redeye leaves an initial comment following the Q3 report published by Magle this morning.
Redeye leaves a comment on the announced completion of the merger between Magle and Amniotics.
Redeye provides a research update following the Q2 report recently published by Magle.
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Redeye leaves a comment following Magle’s announcement of an acquisition of pK Biotech ApS and its subsidiary pK Chemicals A/S.
Redeye leaves a comment following the Magle Group’s announced merger with Amniotics yesterday.
Redeye leaves a short note following Magle’s announcement yesterday of the initial outcome of the public offer to acquire Amniotics and an e...
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Redeye leaves a comment following the Magle Group’s announced public offer to acquire Amniotics earlier today.
Redeye leaves an initial comment following the Q4 report published by Magle this morning.
Redeye leaves a comment on the Q3 report published by Magle yesterday.
Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array of revenue streams.
